We are live on ! Find out more
QNCX icon

Quince Therapeutics
QNCX

42 hedge funds and large institutions have $7.84M invested in Quince Therapeutics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

5% more funds holding

Funds holding: 40 → 42 (+2)

0.02% less ownership

Funds ownership: 0.1% → 0.09% (-0.02%)

7% less capital invested

Capital invested by funds: $8.4M → $7.84M (-$567K)

55% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 11

Holders
42
Holders Change
+2
Holders Change %
+5%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
5
Reduced
11
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$134K
2
SI
Scharf Investments
California
+$91.1K
3
Jane Street
Jane Street
New York
+$44.1K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$42.3K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$21.8K

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$279K
2
ECG
EPIQ Capital Group
California
-$56.5K
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$22K
4
SB
Strategic Blueprint
Georgia
-$13.7K
5
LBC
Lawrence B. Cohen
-$12.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
OPS
26
Orion Portfolio Solutions
Nebraska
$11.4K – – –
WP
27
Westmount Partners
California
$10.7K – – –
TRCT
28
Tower Research Capital (TRC)
New York
$7.09K +$6.81K +34 New
Citigroup
29
Citigroup
New York
$5.42K – – –
PA
30
Parallel Advisors
California
$2.5K – – –
Wells Fargo
31
Wells Fargo
California
$1.33K – – –
ASN
32
Advisory Services Network
Georgia
$1.1K +$1K +5 New
UBS Group
33
UBS Group
Switzerland
$530 -$6.01K -30 -91%
JP Morgan Chase
34
JP Morgan Chase
New York
$492 – – –
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$413 – – –
JFG
36
JDM Financial Group
Texas
$357 – – –
FP
37
Financial Perspectives
Minnesota
$326 – – –
Osaic Holdings
38
Osaic Holdings
Arizona
$290 – – –
Barclays
39
Barclays
United Kingdom
$105 – – –
FA
40
Financial Avengers
California
$105 – – –
WIM
41
Westside Investment Management
California
$79 – – –
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$25 – – –
SB
43
Strategic Blueprint
Georgia
– -$13.7K -61 Closed
LBC
44
Lawrence B. Cohen
– -$12.5K -56 Closed
AF
45
Allworth Financial
California
– -$300 -1 Closed
HGERS
46
Householder Group Estate & Retirement Specialist
Arizona
– -$112 -1 Closed
Simplex Trading
47
Simplex Trading
Illinois
– +$601 +3 New
1
2

QNCX Hedge Fund Activity: Q4 2023 in Review

42 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q4 2023, worth a combined $7.84M — down 6.7% from $8.4M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new QNCX positions and 4 closed out — a net gain of 2 holders — while 5 added to existing stakes and 11 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $134K. The largest seller was Tang Capital Management, cutting an estimated $279K.

  • 42 institutional investors held Quince Therapeutics (QNCX) as of Q4 2023, up from 40 in Q3 2023.
  • Funds reported $7.84M of Quince Therapeutics stock for Q4 2023, down 6.7% quarter-over-quarter.
  • 6 funds opened new Quince Therapeutics positions in Q4 2023 and 4 closed out, a net change of +2 holders.
  • The largest Quince Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $134K added.
  • The largest Quince Therapeutics seller in Q4 2023 was Tang Capital Management, an estimated $279K sold.

Based on aggregated 13F filings for Q4 2023.